Unknown

Dataset Information

0

Actinomycin D Downregulates Sox2 and Improves Survival in Preclinical Models of Recurrent Glioblastoma.


ABSTRACT: BACKGROUND:Glioblastoma  (GBM) has been extensively researched over the last few decades, yet despite aggressive multi-modal treatment, recurrence is inevitable and second-line treatment options are limited. Here, we demonstrate how high throughput screening (HTS) in multicellular spheroids can generate physiologically relevant patient chemosensitivity data using patient-derived cells in a rapid and cost-effective manner. Our HTS system identified ACTD to be highly cytotoxic over a panel of twelve patient-derived glioma stem-like cell lines (GSCs). Actinomycin D (ACTD) is antineoplastic antibiotic used in the treatment of childhood cancers. Here, we validate ACTD as a potential repurposed therapeutic for glioblastoma in three-dimensional GSC cultures and patient-derived xenograft models of recurrent glioblastoma. METHODS:Twelve patient-derived GSCs were screened at 10µM, as multicellular spheroids, in a 384-well serum-free assay with 133 FDA-approved compounds. GSCs were then treated in vitro with ACTD at established IC50 concentrations. Downregulation of Sox2, a stem-cell transcription factor, was investigated via western blot and through immunohistological assessment of murine brain tissue. RESULTS:Treatment with ACTD was shown to significantly reduce tumor growth in two recurrent GBM (rGBM) patient-derived models and significantly increased survival. ACTD is also shown to specifically downregulate the expression of Sox2 both in vitro and in vivo. CONCLUSION:These findings indicate that, as predicted by our HTS, ACTD could deplete the cancer stem cell population within the tumor mass, ultimately leading to a delay in tumor progression.

SUBMITTER: Taylor JT 

PROVIDER: S-EPMC7523458 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Glioblastoma (GBM) has been extensively researched over the last few decades, yet despite aggressive multimodal treatment, recurrence is inevitable and second-line treatment options are limited. Here, we demonstrate how high-throughput screening (HTS) in multicellular spheroids can generate physiologically relevant patient chemosensitivity data using patient-derived cells in a rapid and cost-effective manner. Our HTS system identified actinomycin D (ACTD) to be highly cytotoxi  ...[more]

Similar Datasets

| S-EPMC3158014 | biostudies-literature
| S-EPMC7058445 | biostudies-literature
| S-EPMC6535376 | biostudies-literature
| S-EPMC3828259 | biostudies-literature
| S-EPMC9071332 | biostudies-literature
| S-EPMC10213810 | biostudies-literature
| S-EPMC6010333 | biostudies-literature
| S-EPMC7137265 | biostudies-literature
| S-EPMC7245100 | biostudies-literature
2020-03-05 | GSE146358 | GEO